64 completed. 64 Phase 2, 6 Phase 3, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 64 | Completed 64 |
| Phase 3 | 6 | Completed 6 |
| Phase 1 | 5 | Completed 5 |
Follow Gallbladder Diseases: new trials by email Literature Review of Gallbladder Diseases trials Research Report on Gallbladder Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer Durvalumab, Tremelimumab, Capecitabine - Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 40 | 2022-05-23 | 2025-05-01 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 84 | 2022-04-13 | 2025-06-12 |
| MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib - Uterine Cervical Neoplasms, Endometrial Neoplasms | Phase 2 | Completed | Merck Sharp & Dohme LLC | 611 | 2021-09-16 | 2026-09-28 |
| Low Dose ICG for Biliary Tract and Tumor Imaging Indocyanine green, PINPOINT Endoscopic Fluorescence - Cholecystitis, Hepatocellular Carcinoma | Phase 2 | Completed | University of Florida | 60 | 2021-09-15 | 2023-08-30 |
| Naldebain for Pain Management of Laparoscopic Cholecystectomy Dinalbuphine sebacate, Placebo solution - Pain, Postoperative, Pain, Chronic | Phase 2 / Phase 3 | Completed | E-DA Hospital | 80 | 2021-08-30 | 2022-04-20 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 203 | 2021-03-14 | 2024-04-26 |
| A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients Allocetra-OTS, Placebo - Sepsis, Community-acquired Pneumonia | Phase 2 | Completed | Enlivex Therapeutics Ltd. | 148 | 2020-11-30 | 2025-08-19 |
| A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers ZW25 (Zanidatamab) - HER2-amplified Biliary Tract Cancers | Phase 2 | Completed | Jazz Pharmaceuticals | 87 | 2020-10-01 | 2025-09-15 |
| Ondansetron Effect on Pain Relief After Laparoscopic Cholecystectomy Ondansetron, Normal saline - Cholecystitis | Phase 2 | Completed | National Hepatology & Tropical Medicine Research Institute | 50 | 2020-07-15 | 2021-01-12 |
| A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL) - Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms | Phase 1 / Phase 2 | Completed | Intima Bioscience, Inc. | 23 | 2020-05-15 | 2026-02-23 |
| Pembrolizumab in Biliary Tract Cancer Pembrolizumab, Cisplatin, Gemcitabine - Biliary Tract Cancer, Metastatic Cancer | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 50 | 2020-01-07 | 2023-11-03 |
| Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer Irinotecan, Irinotecan Hydrochloride, Trifluridine and Tipiracil Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Completed | Mayo Clinic | 28 | 2019-10-18 | 2023-08-09 |
| M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) M7824 - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 159 | 2019-03-26 | 2023-10-25 |
| Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients Durvalumab, Gemcitabine, Cisplatin - Cholangiocarcinoma, Gall Bladder Carcinoma | Phase 2 | Completed | AIO-Studien-gGmbH | 128 | 2018-05-02 | 2023-06-15 |
| Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Atezolizumab, Biopsy, Biospecimen Collection - Gallbladder Carcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2018-02-08 | 2024-04-05 |
| Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine - Biliary Tract Cancer | Phase 2 | Completed | ASLAN Pharmaceuticals | 62 | 2017-12-19 | 2020-11-19 |
| TAS-102 in Treating Advanced Biliary Tract Cancers Laboratory Biomarker Analysis, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 - Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7 | Phase 2 | Completed | Mayo Clinic | 28 | 2017-10-20 | 2023-06-28 |
| Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine, Placebo (for Varlitinib) - Biliary Tract Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 151 | 2017-07-04 | 2021-08-03 |
| Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine - Biliary Tract Neoplasms, Cholangiocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2017-06-14 | 2021-12-03 |
Showing 20 of 64. Sign in to see all of them.
Gallbladder Neoplasms (55) · Bile Duct Neoplasms (26) · Cholangiocarcinoma (23) · Biliary Tract Neoplasms (14) · Carcinoma, Hepatocellular (13) · Liver Neoplasms (8) · Pancreatic Neoplasms (6) · Stomach Neoplasms (6) · Neoplasms (5) · Cholecystitis (4) · Neoplasm Metastasis (4) · Esophageal Neoplasms (3) · Gallstones (3) · Klatskin Tumor (3)
Digestive System Diseases (64) · Biliary Tract Diseases (63) · Neoplasms by Site (56) · Digestive System Neoplasms (55) · Neoplasms (51) · Biliary Tract Neoplasms (41) · Neoplasms by Histologic Type (35) · Neoplasms, Glandular and Epithelial (35) · Adenocarcinoma (34) · Carcinoma (33) · Bile Duct Diseases (25) · Liver Diseases (17) · Pathological Conditions, Signs and Symptoms (11) · Endocrine Gland Neoplasms (9)
Gemcitabine (21) · Capecitabine (14) · Cisplatin (9) · Oxaliplatin (8) · Fluorouracil (5) · Bevacizumab (4) · Erlotinib Hydrochloride (4) · Leucovorin (4) · Sorafenib (3) · durvalumab (3) · pembrolizumab (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Carboplatin (2) · Cholecystectomy, Laparoscopic (2)
National Cancer Institute (NCI) (11) · Alliance for Clinical Trials in Oncology (3) · M.D. Anderson Cancer Center (3) · ASLAN Pharmaceuticals (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Mayo Clinic (2) · Memorial Sloan Kettering Cancer Center (2) · Roswell Park Cancer Institute (2) · SWOG Cancer Research Network (2) · TransThera Sciences (Nanjing), Inc. (2) · Washington University School of Medicine (2) · AIO-Studien-gGmbH (1) · All India Institute of Medical Sciences (1) · Chinese University of Hong Kong (1) · Copenhagen University Hospital, Rigshospitalet (1)
United States (43) · China (8) · Spain (7) · France (5) · Germany (4) · Italy (4) · Japan (4) · South Korea (4) · Taiwan (4) · Canada (3) · Sweden (3) · United Kingdom (3) · Chile (2) · Egypt (2) · Israel (2)
Steven R. Alberts, MD (3) · Amit Mahipal (2) · Anthony El-Khoueiry (2) · Benjamin Tan, M.D. (2) · Tanios Bekaii-Saab (2) · Alaa M Sewefy, MD (1) · Ali Zarrinpar, MD, PhD (1) · Allyson Ocean (1) · Anders Johnsson, MD, PhD (1) · Aram Hezel, MD (1) · Arndt Vogel, Prof. Dr. (1) · Bruno Chauffert (1) · Dieter Koeberle, MD (1) · Edgar Ben-Josef, MD (1)
PMID 12794246, PMID 15558814, PMID 18669454, PMID 18669455, PMID 19023677, PMID 19737952, PMID 20662793, PMID 20981545, PMID 21556747, PMID 23640665, PMID 25241229, PMID 25538178, PMID 25964250, PMID 28388942, PMID 30998813, PMID 31254596, PMID 32165407, PMID 32461347, PMID 33289918, PMID 34907910, PMID 35274717, PMID 36728303, PMID 36999533, PMID 37276871, PMID 37339254, PMID 38087967, PMID 39114870, PMID 40315882, PMID 40673842
U10CA032102 (4), 2023 (2), N01CM17104 (2), N01CM62201 (2), 2017 (1), 2018 (1), N01CM00070 (1), N01CM62204 (1), N01CM62207 (1), N01CM62209 (1), P30CA008748 (1), P30CA015083 (1), P30CA016058 (1), U01CA062505 (1), U10CA180888 (1)